Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cogent Biosciences, Inc.NASDAQ: COGT
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $31.83M rose 137.9% year over year, ahead of the +101.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at +34.4% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +46.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $31.83M+12.7% QoQ
- Last fiscal yearDec 2025
- $63.58M+46.9% YoY
- LTMJun 2026
- $98.37M+101.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +137.9% | -100.0% | -237.9 pp |
| 1 year | +46.9% | -100.0% | -146.9 pp |
| 3-year CAGR | +34.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 63.58M USD
- Year-over-year change
- +46.9%
- 4-year CAGR
- +34.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.58M | +46.9% |
| FY2024 | 2024-12-31 | 43.28M | +25.9% |
| FY2023 | 2023-12-31 | 34.38M | +31.1% |
| FY2022 | 2022-12-31 | 26.21M | +33.5% |
| FY2021 | 2021-12-31 | 19.64M | — |
Selling, General & Admin vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's LTM Jun 2026 selling, general & admin of $98.37M is the 5th highest of the 10 companies compared; the peer median is $78.21M.
- Its year-over-year change of +101.7% is the highest of 10, against a peer median of +57.0%.
- Over three fiscal years its annual growth of +34.4% compares with a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B | +8.2% | +11.2% | 24.0% | |
| LTM Mar 2026 | $176.24M | +26.9% | +75.5% | 81.2% | |
| LTM Mar 2026 | $128.35M | +57.4% | +36.6% | 179.2% | |
| LTM Jun 2026 | $106M | -7.8% | +1.9% | 90.6% | |
| LTM Jun 2026 | $98.37M | +101.7% | +34.4% | — | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Sep 2026 | $76.77M | +79.2% | +11.4% | — | |
| LTM Mar 2026 | $69.19M | +65.4% | +42.7% | 30.7% | |
| LTM Mar 2026 | $39.04M | +38.9% | +14.7% | 195.2% | |
| LTM Mar 2026 | $27.19M | +59.1% | +55.2% | — | |
| Peer median (excluding COGT) | $78.21M | +57.0% | +14.7% | 81.2% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.62M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Selling, General & Admin | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Operating Expenses | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| EBITDA | (72.13M) | (130.37M) | (188.82M) | (251.51M) | (321.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (75.55M) | (147.84M) | (208.13M) | (275.94M) | (333.36M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 467K | 3.99M | 13.08M | 18.09M | 14.69M |
| Interest Expense | 0 | 3.99M | 0 | 0 | 3.06M |
| Other Income / Expenses | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M |
| Income Before Tax | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| EPS (Diluted) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| Weighted Avg Shares | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
| Weighted Avg Shares (Diluted) | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.